Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

The Effect Of A Newborn Telehealth Program On Transfers Avoided: A Multiple-Baseline Study.

Albritton J, Maddox L, Dalto J, Ridout E, Minton S.

Health Aff (Millwood). 2018 Dec;37(12):1990-1996. doi: 10.1377/hlthaff.2018.05133.

PMID:
30633672
2.

The potential of transdermal nitric oxide treatment for diabetic peripheral neuropathy and diabetic foot ulcers.

Walton DM, Minton SD, Cook AD.

Diabetes Metab Syndr. 2018 Jul 17. pii: S1871-4021(18)30270-4. doi: 10.1016/j.dsx.2018.07.003. [Epub ahead of print] Review.

PMID:
30030157
3.

Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.

Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L.

J Clin Oncol. 2018 Jul 1;36(19):1981-1990. doi: 10.1200/JCO.2018.78.0858. Epub 2018 May 2.

PMID:
29718793
4.

A phase I study of indoximod in patients with advanced malignancies.

Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ.

Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216.

5.

Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.

Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, Ruiz E, Martinez G, Minton S, Gillies RJ, Gatenby RA.

Sci Transl Med. 2016 Feb 24;8(327):327ra24. doi: 10.1126/scitranslmed.aad7842.

6.

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.

Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, Hille D, Mauro D, Stein MN, Wang-Gillam A, Trull L, Lockhart AC.

Invest New Drugs. 2016 Feb;34(1):84-95. doi: 10.1007/s10637-015-0306-7. Epub 2015 Dec 1.

7.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

8.

Pilot study of Iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer.

Jacobsen PB, Muchnick S, Marcus S, Amheiser P, Reiersen P, Gonzalez B, Gomez M, Jim HS, Thompson LM, Minton S, Bower J.

Psychooncology. 2015 Nov;24(11):1578-80. doi: 10.1002/pon.3756. Epub 2015 Jan 28. No abstract available.

9.

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.

Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S.

Oncotarget. 2014 Sep 30;5(18):8136-46.

10.

Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistance.

Kam Y, Das T, Minton S, Gatenby RA.

Womens Health (Lond). 2014 Jul;10(4):423-30. doi: 10.2217/whe.14.23. Review.

11.

Why do four NICUs using identical RBC transfusion guidelines have different gestational age-adjusted RBC transfusion rates?

Henry E, Christensen RD, Sheffield MJ, Eggert LD, Carroll PD, Minton SD, Lambert DK, Ilstrup SJ.

J Perinatol. 2015 Feb;35(2):132-6. doi: 10.1038/jp.2014.171. Epub 2014 Sep 25.

PMID:
25254330
12.

Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges".

Kam Y, Das T, Tian H, Foroutan P, Ruiz E, Martinez G, Minton S, Gillies RJ, Gatenby RA.

Int J Cancer. 2015 Feb 15;136(4):E188-96. doi: 10.1002/ijc.29158. Epub 2014 Sep 2.

13.

Teleneonatology: a major tool for the future.

Minton S, Allan M, Valdes W.

Pediatr Ann. 2014 Feb;43(2):e50-5. doi: 10.3928/00904481-20140127-11.

PMID:
24512162
14.

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S.

J Hematol Oncol. 2014 Jan 3;7:1. doi: 10.1186/1756-8722-7-1.

15.

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.

Zheng XQ, Guo JP, Yang H, Kanai M, He LL, Li YY, Koomen JM, Minton S, Gao M, Ren XB, Coppola D, Cheng JQ.

Oncogene. 2014 Oct 16;33(42):4985-96. doi: 10.1038/onc.2013.444. Epub 2013 Oct 28.

16.

Evolutionary approaches to prolong progression-free survival in breast cancer.

Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA.

Cancer Res. 2012 Dec 15;72(24):6362-70. doi: 10.1158/0008-5472.CAN-12-2235. Epub 2012 Oct 12.

17.

HER2-positive male breast cancer with thyroid cancer: an institutional report and review of literature.

Bardhan P, Bui MM, Minton S, Loftus L, Carter WB, Laronga C, Ismail-Khan R.

Ann Clin Lab Sci. 2012 Spring;42(2):135-9. Review.

PMID:
22585608
18.

Factors associated with breast cancer worry 3 years after completion of adjuvant treatment.

Phillips KM, McGinty HL, Gonzalez BD, Jim HS, Small BJ, Minton S, Andrykowski MA, Jacobsen PB.

Psychooncology. 2013 Apr;22(4):936-9. doi: 10.1002/pon.3066. Epub 2012 Mar 15.

19.

Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE.

J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9.

20.

History of major depressive disorder prospectively predicts worse quality of life in women with breast cancer.

Jim HS, Small BJ, Minton S, Andrykowski M, Jacobsen PB.

Ann Behav Med. 2012 Jun;43(3):402-8. doi: 10.1007/s12160-011-9333-6.

21.

Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer.

Haviland R, Eschrich S, Bloom G, Ma Y, Minton S, Jove R, Cress WD.

PLoS One. 2011;6(10):e24923. doi: 10.1371/journal.pone.0024923. Epub 2011 Oct 27.

22.

Male breast cancer: management and follow-up recommendations.

Kiluk JV, Lee MC, Park CK, Meade T, Minton S, Harris E, Kim J, Laronga C.

Breast J. 2011 Sep-Oct;17(5):503-9. doi: 10.1111/j.1524-4741.2011.01148.x. Epub 2011 Aug 29.

PMID:
21883641
23.

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.

Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW 2nd, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J.

Clin Breast Cancer. 2011 Apr;11(2):82-92. doi: 10.1016/j.clbc.2011.03.005. Epub 2011 Apr 11. Erratum in: Clin Breast Cancer. 2011 Aug;11(4):273.

24.

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE.

Br J Cancer. 2011 Jun 7;104(12):1828-35. doi: 10.1038/bjc.2011.156. Epub 2011 May 10.

25.

Relationship of exercise to quality of life in cancer patients beginning chemotherapy.

Faul LA, Jim HS, Minton S, Fishman M, Tanvetyanon T, Jacobsen PB.

J Pain Symptom Manage. 2011 May;41(5):859-69. doi: 10.1016/j.jpainsymman.2010.07.019. Epub 2011 Feb 18.

26.

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A.

Br J Cancer. 2009 Oct 6;101(7):1044-50. doi: 10.1038/sj.bjc.6605293. Epub 2009 Sep 8.

27.

Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.

Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D.

Clin Cancer Res. 2009 Apr 1;15(7):2488-96. doi: 10.1158/1078-0432.CCR-08-1930. Epub 2009 Mar 24.

28.

Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.

Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D.

Cancer. 2008 Nov 15;113(10):2646-54. doi: 10.1002/cncr.23916.

29.

What is the role of astrocyte calcium in neurophysiology?

Agulhon C, Petravicz J, McMullen AB, Sweger EJ, Minton SK, Taves SR, Casper KB, Fiacco TA, McCarthy KD.

Neuron. 2008 Sep 25;59(6):932-46. doi: 10.1016/j.neuron.2008.09.004. Review.

30.

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.

Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A.

J Clin Oncol. 2007 May 20;25(15):1979-85.

PMID:
17513804
31.

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.

Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW.

Clin Cancer Res. 2007 Feb 15;13(4):1238-45.

32.

Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.

Cox CE, Cox JM, White LB, Stowell NG, Clark JD, Allred N, Meyers M, Dupont E, Furman B, Minton S.

Ann Surg Oncol. 2006 Apr;13(4):483-90. Epub 2006 Mar 7.

PMID:
16523361
33.

Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.

Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA.

Clin Cancer Res. 2006 Jan 1;12(1):20-8.

34.

Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells.

Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R.

Clin Cancer Res. 2006 Jan 1;12(1):11-9.

35.

Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo.

Abell AN, Rivera-Perez JA, Cuevas BD, Uhlik MT, Sather S, Johnson NL, Minton SK, Lauder JM, Winter-Vann AM, Nakamura K, Magnuson T, Vaillancourt RR, Heasley LE, Johnson GL.

Mol Cell Biol. 2005 Oct;25(20):8948-59.

36.

Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit?

Kumar N, Allen KA, Riccardi D, Bercu BB, Cantor A, Minton S, Balducci L, Jacobsen PB.

Breast Cancer Res Treat. 2004 Jan;83(2):149-59.

PMID:
14997046
37.

Operational evaluation of pulse oximetry in NICU patients with arterial access.

Gerstmann D, Berg R, Haskell R, Brower C, Wood K, Yoder B, Greenway L, Lassen G, Ogden R, Stoddard R, Minton S.

J Perinatol. 2003 Jul-Aug;23(5):378-83.

38.

Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer.

Minton SE, Munster PN.

Cancer Control. 2002 Nov-Dec;9(6):466-72. Review.

PMID:
12514564
39.

A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer.

Weitzner MA, Moncello J, Jacobsen PB, Minton S.

J Pain Symptom Manage. 2002 Apr;23(4):337-45.

PMID:
11997203
40.

Childhood outcome after early high-frequency oscillatory ventilation for neonatal respiratory distress syndrome.

Gerstmann DR, Wood K, Miller A, Steffen M, Ogden B, Stoddard RA, Minton SD.

Pediatrics. 2001 Sep;108(3):617-23.

PMID:
11533327
41.

Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R.

Oncogene. 2001 May 3;20(20):2499-513.

42.

Temporary reversal of anticoagulation using oral vitamin K.

White RH, Minton SM, Andya MD, Hutchinson R.

J Thromb Thrombolysis. 2000 Oct;10(2):149-53.

PMID:
11005937
43.

New Hormonal Therapies for Breast Cancer.

Minton SE.

Cancer Control. 1999 May;6(3):247-255.

PMID:
10758554
44.

Breast Cancer Treatment: Prospects for the Future.

Minton SE.

Cancer Control. 1999 May;6(3):215-217. No abstract available.

PMID:
10758551
45.

Chemoprevention of breast cancer in the older patient.

Minton SE.

Hematol Oncol Clin North Am. 2000 Feb;14(1):113-30. Review.

PMID:
10680075
46.

Severe Lhermitte-Duclos disease with unique germline mutation of PTEN.

Sutphen R, Diamond TM, Minton SE, Peacocke M, Tsou HC, Root AW.

Am J Med Genet. 1999 Feb 12;82(4):290-3.

PMID:
10051160
47.

Menopausal Status and the Impact of Early Recurrence on Breast Cancer Survival.

Lyman GH, Kuderer NM, Lyman SL, Debus M, Minton S, Balducci L, Horton J, Reintgen D, Cox C.

Cancer Control. 1997 Jul;4(4):335-341.

PMID:
10763039
48.

Nurse/physician collaborative practice: improving health care quality while decreasing cost.

Lassen AA, Fosbinder DM, Minton S, Robins MM.

Nurs Econ. 1997 Mar-Apr;15(2):87-91, 104.

PMID:
9146258
49.

The Provo multicenter early high-frequency oscillatory ventilation trial: improved pulmonary and clinical outcome in respiratory distress syndrome.

Gerstmann DR, Minton SD, Stoddard RA, Meredith KS, Monaco F, Bertrand JM, Battisti O, Langhendries JP, Francois A, Clark RH.

Pediatrics. 1996 Dec;98(6 Pt 1):1044-57.

PMID:
8951252
50.

Bites by non-native venomous snakes in the United States.

Minton SA.

Wilderness Environ Med. 1996 Nov;7(4):297-303.

PMID:
11990127

Supplemental Content

Loading ...
Support Center